RMC-5552 is a potent and selective mTORC1 inhibitor. RMC-5552 inhibits phosphorylation of mTORC1 pS6K and p4EBP1 with IC 50 s of 0.14 nM and 0.48 nM, respectively. RMC-5552 shows much lower pAKT inhibition (IC 50 of 19 nM), resulting in mTORC1/mTORC2 selectivity approaching 40-fold. RMC-5552 has anti-cancer activity.
性状
Solid
IC50 & Target[1][2]
mTORC1
体外研究(In Vitro)
FKBP12 的存在,只有在 RMC-5552 的 FKBP12-FRB 变构模态存在的情况下才能观察到其募集。RMC-5552 的密度在 FKBP12 和 mTOR 的 FRB 域之间的界面处很明显。RMC-5552 通过 4-氨基吡唑并 [3,4-d] 嘧啶核心与 G2238 和 V2240 的主链形成氢键,mTOR 的“铰链”,2-氨基苯并恶唑与 E2190 和 K2187 形成氢键相互作用。 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
RMC-5552 (1-10 mg/kg;腹腔注射;一周一次;共 28 天) 在小鼠体内 MCF-7 乳腺癌人异种移植模型中表现出抗肿瘤活性。
RMC-5552 在小鼠中的 PK 参数,通过 IP 给药 1 mg/kg
compounds
T max (h)
C max (ng/mL)
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. G Leslie Burnett, et al. Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors. J Med Chem. 2022 Dec 19.
溶解度数据
In Vitro: DMSO : 166.67 mg/mL (93.73 mM; Need ultrasonic)配制储备液